Book contents
- The Clozapine Handbook
- The Clozapine Handbook
- Copyright page
- Additional material
- Contents
- Foreword
- Introduction
- 1 The Efficacy Story: Treatment-Resistant Schizophrenia, Psychogenic Polydipsia, Treatment-Intolerant Schizophrenia, Suicidality, Violence, Mania and Parkinson’s Disease Psychosis
- 2 Addressing Clozapine Positive Symptom Nonresponse in Schizophrenia Spectrum Patients
- 3 Initiating Clozapine
- 4 Discontinuing Clozapine and Management of Cholinergic Rebound
- 5 Binding Profile, Metabolism, Kinetics, Drug Interactions and Use of Plasma Levels
- 6 Understanding Hematologic Monitoring and Benign Ethnic Neutropenia
- 7 Managing Constipation
- 8 Managing Sedation, Orthostasis and Tachycardia
- 9 Managing Sialorrhea
- 10 Managing Seizure Risk and Stuttering
- 11 Managing Metabolic Adverse Effects
- 12 Fever, Myocarditis, Interstitial Nephritis, DRESS, Serositis and Cardiomyopathy
- 13 Managing Enuresis and Incontinence, Priapism, Venous Thromboembolism, Neuroleptic Malignant Syndrome, Tardive Dyskinesia and Obsessive Compulsive Disorder
- 14 Eosinophilia, Leukocytosis, Thrombocytopenia, Thrombocytosis, Anemia, Hepatic Function Abnormalities
- 15 Special Topics: Child and Adolescent Patients, Elderly Patients, Patients With Intellectual Disability, Pregnancy and Risk for Major Congenital Malformation, Lactation, Overdose, Postmortem Redistribution
- Index
- References
Introduction
Published online by Cambridge University Press: 19 October 2021
Book contents
- The Clozapine Handbook
- The Clozapine Handbook
- Copyright page
- Additional material
- Contents
- Foreword
- Introduction
- 1 The Efficacy Story: Treatment-Resistant Schizophrenia, Psychogenic Polydipsia, Treatment-Intolerant Schizophrenia, Suicidality, Violence, Mania and Parkinson’s Disease Psychosis
- 2 Addressing Clozapine Positive Symptom Nonresponse in Schizophrenia Spectrum Patients
- 3 Initiating Clozapine
- 4 Discontinuing Clozapine and Management of Cholinergic Rebound
- 5 Binding Profile, Metabolism, Kinetics, Drug Interactions and Use of Plasma Levels
- 6 Understanding Hematologic Monitoring and Benign Ethnic Neutropenia
- 7 Managing Constipation
- 8 Managing Sedation, Orthostasis and Tachycardia
- 9 Managing Sialorrhea
- 10 Managing Seizure Risk and Stuttering
- 11 Managing Metabolic Adverse Effects
- 12 Fever, Myocarditis, Interstitial Nephritis, DRESS, Serositis and Cardiomyopathy
- 13 Managing Enuresis and Incontinence, Priapism, Venous Thromboembolism, Neuroleptic Malignant Syndrome, Tardive Dyskinesia and Obsessive Compulsive Disorder
- 14 Eosinophilia, Leukocytosis, Thrombocytopenia, Thrombocytosis, Anemia, Hepatic Function Abnormalities
- 15 Special Topics: Child and Adolescent Patients, Elderly Patients, Patients With Intellectual Disability, Pregnancy and Risk for Major Congenital Malformation, Lactation, Overdose, Postmortem Redistribution
- Index
- References
Summary
The year 2018 marked the 60th anniversary of clozapine’s synthesis, and the 30th anniversary of the September 1988 Archives of General Psychiatry paper by Kane and colleagues documenting clozapine’s superior efficacy in treatment-resistant schizophrenia. The peer view literature since 1988 demonstrates ongoing interest in clozapine, with 350–450 papers per year listed in PubMed (see Figure 1). The ensuing decades have also seen other evidence-based uses for clozapine (e.g. schizophrenia patients with suicidality or aggression, Parkinson’s disease psychosis, treatment-resistant mania), but treatment-resistant schizophrenia spectrum disorders remain the most common indication. Lamentably, clozapine remains significantly underutilized for treatment-resistant schizophrenia despite compelling evidence of efficacy in this population, and the enormous individual and societal benefits that can accrue from effective management of treatment-resistant patients.
- Type
- Chapter
- Information
- The Clozapine HandbookStahl's Handbooks, pp. 1 - 9Publisher: Cambridge University PressPrint publication year: 2019
References
Kane, J., Honigfeld, G., Singer, J., et al. (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789–796.CrossRefGoogle ScholarPubMed
Kelly, D. L., Freudenreich, O., Sayer, M. A., et al. (2018). Addressing barriers to clozapine underutilization: a national effort. Psychiatric Services, 69, 224–227.CrossRefGoogle ScholarPubMed
Charlson, F. J., Ferrari, A. J., Santomauro, D. F., et al. (2018). Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016. Schizophrenia Bulletin, 44, 1195–1203.Google Scholar
Vos, T., Abajobir, A. A., Abbafati, C., et al. (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390, 1211–1259.CrossRefGoogle Scholar
Cloutier, M., Aigbogun, M. S., Guerin, A., et al. (2016). The economic burden of schizophrenia in the United States in 2013. Journal of Clinical Psychiatry, 77, 764–771.CrossRefGoogle ScholarPubMed
Kennedy, J. L., Altar, C. A., Taylor, D. L., et al. (2014). The social and economic burden of treatment-resistant schizophrenia: A systematic literature review. International Clinical Psychopharmacology, 29, 63–76.Google Scholar
Howes, O. D., McCutcheon, R., Agid, O., et al. (2017). Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. American Journal of Psychiatry, 174, 216–229.CrossRefGoogle Scholar
Stroup, T. S., Gerhard, T., Crystal, S., et al. (2014). Geographic and clinical variation in clozapine use in the United States. Psychiatric Services, 65, 186–192.CrossRefGoogle ScholarPubMed
Downs, J. and Zinkler, M. (2007). Clozapine: National review of postcode prescribing. Psychiatric Bulletin, 31, 384–387.Google Scholar
Sultan, R. S., Olfson, M., Correll, C. U., et al. (2017). Evaluating the effect of the changes in FDA guidelines for clozapine monitoring. Journal of Clinical Psychiatry, 78, e933–e939.CrossRefGoogle ScholarPubMed
Cohen, D. (2014). Prescribers fear as a major side-effect of clozapine. Acta Psychiatrica Scandinavica, 130, 154–155.Google Scholar
Nielsen, J., Dahm, M., Lublin, H., et al. (2010). Psychiatrists’ attitude towards and knowledge of clozapine treatment. Journal of Psychopharmacology, 24, 965–971.CrossRefGoogle ScholarPubMed
Grover, S., Balachander, S., Chakarabarti, S., et al. (2015). Prescription practices and attitude of psychiatrists towards clozapine: A survey of psychiatrists from India. Asian Journal of Psychiatry, 18, 57–65.CrossRefGoogle ScholarPubMed
Tungaraza, T. E. and Farooq, S. (2015). Clozapine prescribing in the UK: Views and experience of consultant psychiatrists. Therapeutic Advances in Psychopharmacology, 5, 88–96.CrossRefGoogle ScholarPubMed
Carruthers, J., Radigan, M., Erlich, M. D., et al. (2016). An initiative to improve clozapine prescribing in New York State. Psychiatric Services, 67(4), 369–371.CrossRefGoogle ScholarPubMed
Olfson, M., Gerhard, T., Crystal, S., et al. (2016). Clozapine for schizophrenia: state variation in evidence-based practice. Psychiatric Services, 67, 152.Google Scholar